Looks like we need to wait a bit longer for results...
"According to Barvarian Nordic, the key results of the Phase III clinical trial of the immunologic agent Prostvac (rilimogene galvacirepvec/rilimogene glafolivec, or “rilimogene”) in treatment of metastatic, castration-resistant prostate cancer (mCRPC) are now expected in the second half of 2017."
/prostatecancerinfolink.net/2017/01/05/results-of-prostvac-prospect-trial-scheduled-for-later-in-2017/